Introduction
It is well recognized that cells of the monocyte/macrophage lineage are capable of fusion to form multinucleated giant cells (MGCs). However, many aspects of their recognition, adhesion, fusion, and activation, in addition to specific intercellular and intracellular signaling pathways, remain unknown [1 ,2 ] . MGC phenotypes vary, depending on the local environment and the chemical and physical (size) nature of the agent to which the MGCs and their monocyte/macrophage precursors are responding.
This review focuses on recent efforts to develop a better understanding of the molecular and cellular biology of MGC formation and function. Recent studies on four different types of MGCs are presented: giant cells from mycobacterium-induced granulomas, giant cell tumors of bone, osteoclast formation and function, and foreign body giant cell (FBGC) formation and function. The review ends with a conclusion section that identifies future issues and possible problems in our further elucidation of the molecular and cellular biology of MGCs.
Giant cells from mycobacterium-induced granulomas
In studies utilizing an in-vitro model of human tuberculous granulomas, Lay et al. [3 ] have shown that highvirulence mycobacterium, that is, Mycobacterium tuberculosis, induces large MGCs with more than 15 nuclei per cell, whereas with low-virulence mycobacterium species, Mycobacterium avium and Mycobacterium smegmatis, they have low numbers of nuclei per cell, less than seven. Of special note is that the high-virulence mycobacterium species resulted in granulomas where the MGC phagocytic activity was absent, as opposed to the low-virulence species that produced MGCs where phagocytic activity was present; all species demonstrated the presence of MGC NADP oxidative activity [3 ] . MGCs with high numbers of nuclei per cell and produced by highly virulent mycobacteria are considered the final stage of formation or differentiation of MGCs or both, as these cells are incapable of phagocytosis but still retain a strong antigen-presentation capability. The authors consider that this model of human tuberculous granulomas enables the analysis of well defined and well differentiated Purpose of review To provide insight into the current state of understanding regarding the molecular and cellular mechanisms underlying the formation and function of various types of multinucleated giant cells.
Recent findings
Recent studies involving mainly osteoclasts and foreign body giant cells have revealed a number of common factors, for example, vitronectin, an adhesion protein, dendritic cellspecific transmembrane protein, a fusion factor, and macrophage fusion receptor, that contribute to giant cell formation and function. Insight into common molecules, receptors, and mediators of adhesion and fusion mechanisms of giant cell formation have been complicated by the wide diversity of species, models, and cell types utilized in these studies.
Summary
These recently identified factors together with the well known osteoclast receptor, a v b 3 , may serve as potential therapeutic targets for the modulation and inhibition of multinucleated giant cell formation and function. Further studies on intracellular and intercellular signaling mechanisms modulating multinucleated giant cell formation and function are necessary for the identification of therapeutic targets as well as a better understanding of giant cell biology.
granulomatous structures, consisting of all the specific cell types found within natural human granulomas, unlike those developed from other species. This in-vitro human granuloma model also has been used to identify the role of mycobacterial envelope glycolipids in granuloma formation [4 ] . In this model, mycobacterial proinflammatory phosphatidyl-myo-inositol mannosides and lipomannans and anti-inflammatory lipoarabinomannan induce granuloma formation. However, only proinflammatory glycolipids induce the fusion of granuloma macrophages into MGCs, and this process occurs through a Toll-like receptor 2-dependent, ADAM9 and b1 integrin-mediated pathway. These findings relating substrate chemistry and the upregulation of b1 in the macrophage differentiation and MGC fusion and formation processes are similar to those identified for FBGC development on foreign substrates, as described later.
Giant cell tumors of bone
Giant cell tumors of bone are normally found in metaepiphyseal regions, forming after skeletal maturity [5] . Following initial tumor formation, mononuclear histiocytic cells are recruited to the site of the tumor and fuse to form MGCs. Receptor activator of nuclear factor kB (NF-kB) ligand (RANKL) is expressed by neoplastic giant cell tumor stromal cells, promoting fusion with macrophage colony-stimulating factor (M-CSF) acting as a cofactor.
Giant cell tumors are composed of mononuclear histiocytic cells, MGCs, considered to belong to the monocytic-histiocytic system, and proliferating neoplastic tumor cells, also called giant cell tumor stromal cells (GCTSCs), that do not belong to the monocytic-histiocytic system. Nishimura et al. [6] have demonstrated that soluble factors from the GCTSCs can induce MGC formation from monocytes. These MGCs have characteristic biomarkers suggestive of osteoclasts. GCTSCs can facilitate the chemoattraction of mononuclear histiocytes as well as the formation of MGCs. Gene expression of GCTSCs suggests that these stromal cells are of early osteoblastic differentiation and also show differentiation features of mesenchymal stem cells.
Osteoclast formation and function
Osteoclasts are multinucleated bone-resorbing cells that play a pivotal role in bone homeostasis and remodeling. Osteoclast precursors derive from bone marrow as early mononuclear macrophages, circulate in blood, and bind to the surface of bone. Although the mechanism of recognition and target binding present on bone's surface is unknown, the integrin a v b 3 is the dominant osteoclast integrin and the marker of osteoclast phenotype [7] , which is initially absent on macrophage precursors but progressively induced by RANKL. The a v b 3 integrin recognizes the Arg-Gly-Asp (RGD) tripeptide sequence in several extracellular matrix macromolecules such as osteopontin, which is abundant in bone, as well as fibronectin, vitronectin, and fibrinogen. In addition to the high osteoclast expression of a v b 3 , mammalian osteoclasts express a 2 b 1 , a collagen-laminin receptor, and a v b 1 , another vitronectin receptor.
Osteoclast formation is driven mainly by two cytokines, RANKL and M-CSF. RANKL is a member of the tumor necrosis factor (TNF) superfamily and is considered the essential osteoclastogenic cytokine. It is also expressed on osteoblasts and their precursors, and its production is enhanced by osteoclast-stimulating agents such as parathyroid hormone and TNF-a. Cell surface RANKL interacts with its receptor, RANK, on osteoclast progenitors. Osteoprotegerin is also synthesized by osteoblasts and their precursors and is another member of the TNF superfamily. Osteoprotegerin recognizes RANKL and can thus function as a decoy receptor, competing with RANK. Overproduction of RANKL can lead to osteoporosis, whereas overproduction of osteoprotegerin can lead to osteopetrosis. Inflammatory or periarticular osteolysis, a significant complication of rheumatoid arthritis, is a product of enhanced osteoclast recruitment and activation. As Teitelbaum [8] has clearly expressed, the development of further understanding of the mechanisms by which the receptor activation of NF-kB ligand (RANKL), M-CSF and TNF-a modulate osteoclast behavior and can result in the identification of active and candidate therapeutic targets for the treatment of inflammatory osteolysis.
Osteoporosis results from the enhancement of the rate of bone loss by osteoclasts relative to the bone-forming capacity of osteoblasts. Blockade of the a v b 3 integrin on osteoclasts offers a promising approach for antibone resorptive therapy [9] . The b3 subunit is most commonly identified on osteoclasts, the placenta, and platelets. Although the platelet associates with a different a-integrin subunit, that is, glycoprotein IIb (GPIIb b), development of therapeutic modalities for osteoporosis must be specific and selective for the osteoclast integrin and not sufficiently broad to modulate the behavior of GPIIb b3, in which platelet defects could lead to bleeding dyscrasias [7] .
Yagi et al. [10] , using a knockout mouse model, have identified dendritic cell-specific transmembrane protein (DC-STAMP) as being required for the fusion of both osteoclasts and FBGCs. Osteoclasts derived from the DC-STAMP knockout mice were mononuclear, exhibited bone-resorbing activity, expressed osteoclast markers and cytoskeletal structure, but did not demonstrate cell fusion. Retroviral introduction of DC-STAMP in osteoclast precursors reestablished osteoclast multinucleation. Histological evaluation of Ivalon (crosslinked polyvinyl alcohol) in DC-STAMP knockout mice demonstrated abrogation of multinucleated FBGC formation. In-vitro experiments using interleukin (IL)-3 and IL-4 treatment of macrophages from DC-STAMP knockout mice demonstrated no FBGC formation. These studies clearly identify a common molecule necessary for the multinucleation, that is, cell fusion, of both osteoclasts and FBGCs. Vignery [11] discussed the significance of identifying the ligand for DC-STAMP and determining whether it is a surface protein expressed by macrophages or a soluble protein released by macrophages in a constitutive or regulated manner. Identification of a ligand for DC-STAMP has significant importance in developing therapeutic modalities related to osteoclasts, FBGCs, and macrophage interactions with tumor cells.
Foreign body giant cell formation and function
FBGCs are most commonly observed at the tissue/ material interface of implanted medical devices, prostheses, and biomaterials [2 ]. In this context, adherent macrophages and FBGCs constitute the foreign body reaction (Fig. 1) . FBGCs are also seen in tissues where the size of foreign particulate is too large to permit macrophage phagocytosis. Generally, it is accepted that FBGCs are generated by macrophage fusion and serve the same purpose as osteoclasts, degradation/resorption of the underlying substrate. Table 1 identifies significant differences in factors believed to be important in the formation and function of osteoclasts and FBGCs. Unlike osteoclasts, which adhere to bone, FBGCs, together with their macrophage precursors, adhere to markedly different synthetic surfaces that display distinct differences in hydrophilic/hydrophobic character as well as chemical and physical properties [2 ].
The b1 and b2 integrin receptor families have been identified as necessary and sufficient mediators of adhesion during monocyte-to-macrophage development and IL-4-induced FBGC formation. Further identification of specific alpha partners to these beta integrins has identified the following expression profile for IL-4induced FBGCs: a M b 2 , a X b 2 , a 5 b 1 more than a V b 1 more than a 3 b 1 , and a 2 b 1 [12 ] . Complement components and fibrinogen have been identified as early adhesion ligands to the b2 integrins, and, at later times, vitronectin has been identified as the critical protein adhesion substrate for IL-4-induced FBGC formation [13 ] . This wide variation in integrin receptors and adhesion molecules is most probably the result of the wide and varied surface chemistries presented by synthetic substrates. Helming and Gordon [14 ] have proposed a multistage process involving multiple target molecules for macrophage fusion induced by IL-4 alternative activation. Studies with STAT6 knockout mice have revealed IL-4-induced expression of E-cadherin and DC-STAMP in a STAT6dependent manner. E-cadherin expression was critical for the formation of FBGCs by IL-4. Monocyte/macrophage precursors from the STAT6 knockout mice were not responsive to IL-4 in forming FBGCs and also displayed a lack of phagocytosis [15 ] . Other studies with human monocyte/macrophage precursors demonstrated that FBGC formation exhibited features of phagocytosis with participation of components of the endoplasmic reticulum [16] . The P2X 7 receptor, an ATP-gated ion channel belonging to the family of P2X purinergic receptors, has been implicated in the formation of all three types of MGCs: FBGCs, Langhans' giant cells, and osteoclasts. It has been suggested that P2X 7 is a common molecular step crucial for MGC formation [17] . CD44 receptor expression is highly induced in macrophages at the onset of fusion. The intracellular domain of CD44 (CD44ICD) is cleaved in macrophages undergoing fusion and is localized in the nucleus of fusing macrophages in which it promotes the activation of NF-kB [18] . Connexin 43 has been identified as playing a functional role in gap junction communication and the formation of osteoclast-like FBGCs in response to implantation of nanoparticulate hydroxyapatite [19 ] . These studies have significant implications for hard tissue engineering and the reconstruction of bone defects. In previous studies, T lymphocytes had been identified as a possible source of IL-4 and IL-13 cytokines that induce macrophage fusion. Utilizing three different types of synthetic polymers, Rodriguez et al. [20] demonstrated that FBGC formation and morphology were comparable between normal and T-cell-deficient mice. Although IL-4 was not detected, IL-13 levels were comparable between normal and T-cell-deficient mice. In-vitro cell culture studies using human monocytes/macrophages and lymphocytes demonstrated that proinflammatory cytokines such as IL-b, TNF-a, IL-6, IL-8, and macrophage inflammatory protein (MIP)-1b were upregulated, but no effect on anti-inflammatory IL-10 production was identified. Lymphocyte/macrophage/FBGC interactions through indirect (paracrine) signaling showed a significant effect in enhancing adherent macrophage/FBGC activation at early time points, whereas interactions by direct (juxtacrine) mechanisms dominated at later time points. Biomaterial surface chemistries differentially affected the observed responses with hydrophilic/neutral and hydrophilic/anionic surfaces, evoking the highest levels of adherent cell activation relative to other surfaces [21] . Proteomic analysis and quantification of cytokines and chemokines from biomaterials surface-adherent human macrophages and FBGCs showed significant differences in cytokine/chemokine profiles that were dependent on the polymer surface chemistry and properties. Although hydrophilic surfaces demonstrated a markedly reduced adherent cell density compared with hydrophobic surfaces, the activation level of adherent cells on the hydrophilic surfaces was markedly increased over that on the hydrophobic surfaces. This study clearly demonstrated that material surface chemistry could differentially affect monocyte/macrophage/FBGC adhesion and cytokine/ chemokine profiles derived from activated macrophages/ FBGCs adherent to biomaterial surfaces [22 ,23 ] .
Conclusion
To date, studies on tuberculoid granulomas, osteoclasts, and FBGCs have been complicated, and possibly confused, by the wide diversity of species and cell types that have been used in these studies. Knockout systems have played a significant role in developing a further understanding of cell-cell fusion mechanisms, but the question remains, 'what other pathways and receptor-ligand interactions are compromised in these specific systems?' A clear example is the bleeding dyscrasias produced in b3 56 Myeloid biology integrin knockout systems utilized for osteoclast studies. In regard to FBGCs and their significant in-vivo interactions with medical devices, prostheses, and biomaterials, human and other mammalian blood monocytes, thioglycollate-elicited peritoneal macrophages, and alveolar macrophages have been utilized. Little is known regarding the similarities and differences of the phenotypes of these different monocytes/macrophages.
A better understanding of paracrine, juxtacrine, and endocrine interactions that facilitate and modulate MGC formation is necessary. The strengths and weaknesses of the use of specific species, models, and cell types, as they apply to the human condition, are necessary if mechanisms and signaling pathways are to be clearly delineated. In regard to the FBGC, the increasing utilization of biodegradable and nonbiodegradable synthetic substrates in tissue engineering and regenerative medicine place special significance on developing a better understanding of FBGC formation and function, with the ultimate goal being the inhibition of FBGC formation and its potential adverse effects.
